Wells Fargo analyst Derek Archila downgraded Arvinas to Equal Weight from Overweight with a price target of $49, down from $83.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARVN:
- Arvinas appoints Everett Cunningham to board of directors
- Arvinas Announces Changes to its Board of Directors
- Arvinas price target lowered to $72 from $88 at Citi
- Analysts Say These 2 ‘Strong Buy’ Stocks Are Their Top Picks for 2023
- Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)